Insulet PODD appears well-poised on solid prospects in the diabetes market. The company continues to gain from strong Omnipod 5 and Omnipod DASH uptake globally. The stock carries a Zacks Rank #1 ...

Insulet Corporation PODD is well-poised to gain in the coming quarters, backed by the strength of its revolutionary Omnipod 5 Automated Insulin Delivery (“AID”) system. The continued market expansion ...

Billerica, Massachusetts-based Insulet Corporation, maker of the OmniPod Insulin pump, has just announced that it received the FDA clearance to commercialize its latest product the Omnipod Dash ...

Both moves have shown up in margin expansion. Insulet is currently enjoying adoption of its Omnipod Dash, which allows for access to personal blood glucose and insulin readings from the pump to a ...

Insulet Corporation's Omnipod 5 System received FDA clearance for type 2 diabetes in August. Insulet reported a 26% year-over-year revenue increase in Q2 2024, driven by strong demand for Omnipod 5.

Editor's note: The headline and body of this article has been edited to clarify that Samsung's integration with the Omnipod Dash have not yet been implemented. Samsung Galaxy smartphones will be ...

PODD stock rallies 37.4% in a year, fueled by Omnipod 5 adoption, global launches and expanding reach in diabetes care.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), today announced a Medical Device Correction for the Omnipod® 5 Automated Insulin Delivery System because of ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), announced on October 17, 2022, a Medical Device Correction for all Omnipod DASH® Personal Diabetes Managers (PDMs) distributed globally.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the ...